MSU
DMII

Mizuho Securities USA’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Mizuho Securities USA’s Portfolio DMII Stock Details DMII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,600
Closed -$184K – 747
2026
Q1 		$184K Sell
18,600
-197,707
-91% -$1.97M ﹤0.01% 673
2025
Q4 		$1.26M Buy
+216,307
New +$2.14M 0.02% 532

Other funds holding DMII

CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
MCS
Mercuria Capital Strategies Houston, Texas $163M AUM 258.7% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
TCM
Tuttle Capital Management Riverside, Connecticut $148M AUM 64.07% 1-Year Est. Return

Mizuho Securities USA's DMII Position: Q2 2026 in Review

Mizuho Securities USA sold out of Drugs Made In America Acquisition II Corp (DMII) in Q2 2026, closing a stake of 18,600 shares — an estimated $184K sold.

Mizuho Securities USA first reported a position in DMII in Q4 2025 and held it in 2 quarters. The position peaked at $1.26M in Q4 2025. 7 funds tracked by Wall St. Rank hold DMII as of Q2 2026.

  • Mizuho Securities USA reported no remaining Drugs Made In America Acquisition II Corp position as of Q2 2026 after selling out during the quarter.
  • Mizuho Securities USA sold 18,600 Drugs Made In America Acquisition II Corp shares in Q2 2026, an estimated $184K.
  • Mizuho Securities USA first reported a position in Drugs Made In America Acquisition II Corp in Q4 2025 and held it in 2 quarters.
  • Mizuho Securities USA's Drugs Made In America Acquisition II Corp position peaked at $1.26M in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q2 2026.

Based on Mizuho Securities USA's 13F filing for Q2 2026, filed 24 Jul 2026.